Enterprise Value
2.986B
Cash
5.569M
Avg Qtr Burn
-8.955M
Short % of Float
0.01%
Insider Ownership
0.00%
Institutional Own.
13.80%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Aemcolo® (rifamycin) Details Bacterial infection | Approved Quarterly sales | |
Movantik® (naloxegol) Details Pain, Constipation, Biliary atresia, Liver disease | Approved Quarterly sales | |
Talicia® (omeprazole magnesium, amoxicillin and rifabutin) Details Bacterial infection | Approved Quarterly sales | |
RHB-102 (Bekinda®) Details Digestive tract, Stomach, Intestinal infection | Phase 3 Update | |
RHB-104 Details Inflammatory disease, Crohns disease | Phase 3 Update | |
RHB-102 (Bekinda®) Details Irritable bowel syndrome, Bowel disorder, Post-traumatic stress disorder, Psychiatric disorder | Phase 3 Initiation | |
RHB-107 (upamostat) Details COVID-19 | Phase 2 Data readout | |
Failed Discontinued | ||
RHB-106 Details Bowel preparation , Breast cancer | Failed Discontinued | |
RHB-204 Details Bacterial infection | Failed Discontinued |